Direct answer:Drug Master File (DMF) is used to submit confidential technical information to FDA that can be referenced in other applications for authorization; eCTD is an organizational and life-cycle management format that applies to the content of electronic declarations. The former answers “What documents are submitted for reference” and the latter “how to organize them according to technical requirements”, neither of which amounts to FDA product approval.
I. How do API, pharmastatetical packing and the feed distinguish the DMF type?
- Type II:(b) In relation to substances active in drugs, related intermediates and their preparation materials, or medicines; The scope of the specific document should be judged in conjunction with the applications to be supported.
- Type III:(a) With packaging materials; Decisions on whether to provide information through the DMF should be taken in the light of the use of the material and confidentiality needs.
- Type IV:It involves accessories, pigments, spices, spices and their preparation materials, etc. For further details, seeType IV Supplemental Document Topics。
- Type V:The reference information received by the FDA should be verified first and not be considered a generic category for all types of information.
The type of document does not amount to the vendor having completed all United States compliance obligations. Registration of pharmaceutical facilities, Drug Listing, labelling or specific application requirements should be checked separately and may be combinedAPI, feed and pharmaceutical receiving service directionIdentification of matters to be addressed.
II. How is there a division of labour between Holder, the applicant and the authorized agent?
DMF Holder:Document holders are responsible for organizing information, authorizing references and arranging document maintenance. Legal subjects, technical sources of information, confidential borders and internal authorities should be identified first, and not all information should be handed over to clients.
Quote applicant:To quote the authorized DMF content in your relevant application. One of the purposes of the adoption of the DMF is to enable FDA to review the applicable confidential information without requiring disclosure of the entire document to the citation party.
Agent or service provider:Assistance with organization, transmission, feedback processing or maintenance of information under a clear mandate. The DMF appointing agent and U.S. agent in the register of pharmaceutical facilities should check the duties and authorizations separately and cannot be identified solely on the basis of the same service name.
III. What information is needed before the preparation of the DMF?
- The type of submission to be submitted, the subject matter of the document, the use of the material and the applications to be cited by the client.
- Holder legal name, contact information, related facilities and applicable authorization arrangements.
- Appropriate technical information on the manufacturing process, quality control, specifications, testing, stability or packaging and its catalogue.
- A DMF number, history submission, FDA reply and transaction record is available.
- The proposed authorization of customers and the range of references are documented in LOAs and revocations.
- Current mandate: first submission, technical revision, annual report, transfer or response to FDA questions.
This is the direction of project preparation, and not all DDFs use the same technology catalogue. The depth of the information should be determined by type, material characteristics and the requirements for which it is supported, and gaps should be identified before the workload is estimated.
How do you usually move forward from the first submission to the eCTD submission?
- Identification of uses, types and Holder:Clarify the scope of the document and information responsibilities and check the suitability of the DMF.
- Based on applicable process preparation number:Confirmation of pre-allocation numbers and administrative information; Obtaining a number does not represent that the complete document has been received or reviewed.
- Organization of technical and administrative documentation:Align content, file directory, authorization and signature information, check version and consistency of information.
- Production and verification of electronic submission:The original or follow-up submission is organized according to the applicable eCTD version, technical standards and channels, checking the sequence and technical feedback.
- Retention and processing:Distinguishing between successful transmission, technical receipt, administrative issues and substantive technical review, and recording the status of the stages.
The eCTD is not to put a number of PDFs in compressed packages, nor is it an independent listing approval process. Version support, migration and follow-up sequences should be checked against the current FDA standards and all existing DDFs cannot be immediately recreated simply because a new version appears. See specific areas of collaboration.eCTD Submission Support。
V. How does LOA’s authorized references interface with follow-up maintenance?
The DMF holder or an appropriately authorized representative issues the Letter of Authorization (LOA), identifying the DMF, authorized party and material covered by the reference. Confirm that the authorization matches the customer’s application and submit, provide and retain the applicable records. Sending a DMF number alone does not authorize a reference.
It is available when a communication or authorization is required. DMF LOA Authorised Reference GuideCheck the holder, the applicant and the signature version to be used by both parties.
Changes in technical content, facilities, Holder or contact person should be checked separately for amendments and communications, and the relevant authorized references should be notified. Annual reports, technical revisions, LOAs, new authorizations and withdrawals are different maintenance tasks and cannot leave all changes to the annual reports.
It is recommended that a history series, submission date, current valid version, authorized list and FDA account be established. The transfer of ownership or the replacement of an agent first cross-checks the handover information and the corresponding delegation of authority to avoid documents remaining but not maintained by the enterprise on an ongoing basis.
VI. What is the assessment of the processing cycle and costs of the DMF?
Period:A distinction is made between information preparation, electronic submission, administrative feedback and technical review in the application. Information gaps, type of documents and progress in client applications affect arrangements and therefore it is not appropriate for all DDFs to commit to the same “approval cycle”.
Official costs:Type II API DMF supporting ANDA may involve DMF costs and completeness assessments under GDUFA; This rule cannot be applied directly to all DMF types or to Type II files that only support NDA, IIND. The applicability and amount should be checked against the corresponding items and current official rules.
Services and other costs:Initial preparation, technology gap supplementation, eCTD production, LOA, annual maintenance and question response should be clearly defined; Testing, translation or other third-party work should also be listed separately. Yes.DMF Documentation and Life Cycle Maintenance ServiceSee the cycle and cost composition, and submit project information to communicate offers.
VII. FACTUAL ISSUES
The FDA assigns the DMF number and has the technical information been certified?It cannot be judged on that basis. The FDA does not make a separate approval or rejection decision with respect to the DMF, and its technical content is usually reviewed in conjunction with the specific application to which it is cited.
Do clients have to see the full DMF?Authorisation references do not imply that all confidential information must be disclosed to the client, and that the content of the authorization, customer needs and confidentiality arrangements should be confirmed.
There's a DMF, do you need Drug Listing?The purposes and subjects of application are different and should be judged separately from the activities of enterprises and the role of medicines. ReadableAPI Drug Listing Statement of Responsibility。
Official sources and project portals
- FDA | DMF Use and Review Mechanism
- FDA | DMF Type and Type II API Specific
- FDA | DMF number and submission of resources
- FDA | LOA, Annual Report and other Instruments Template
- FDA | eCTD criteria and current submission resources
Before starting, please describe the type of material, Holder, the applications to be supported, the current number and the status of the information. The DMF technical documentation project needs to identify specific scopes and it is not appropriate to treat generic drug facility registration commodities as full DMF project quotations.
View DMF service and range of processing
Submission of DMF project information, communication information and quotations
Official data checks and updates: 2026-11-06. Author: Mr. Otsun; Audit: Mr. Toto. This is a basic guide to DMF and related electronic declarations, and other master documentation systems and case requirements should be checked separately.
Continue reading and preparation
- Type IV DMF support document: scope of application, content and submission judgement
- API Drug Listing: Who is responsible for submitting the information and whether the information on the customer of the formulation is necessary?
Further consolidation of project information is availableDMF Documentation and Life Cycle Maintenance; The scope, processing cycles and costs are shown on the corresponding service page.